Press releases

* (R) = Regulatory press releases

Sep 25, 2024

(R) Cantargia presents new results at EADV 2024 highlighting the potential of CAN10 treatment in dermatology
Sep 14, 2024

(R) Cantargia presents positive results at ESMO Congress 2024 showing benefit of nadunolimab combination therapy in cancer after relapse on PD1-inhibitors
Sep 9, 2024

(R) Cantargia: new data from two clinical studies strongly support nadunolimab efficacy after relapse on PD1-inhibitors
Aug 28, 2024

(R) Correction: Cantargia publishes half-year report 2024
Aug 28, 2024

(R) Cantargia publishes half-year report 2024
Aug 27, 2024

Cantargia reports presentation of new preclinical data supporting CAN10 in fibrotic lung diseases
Aug 27, 2024

(R) Cantargia reports timelines for nadunolimab clinical trials in leukemia and triple negative breast cancer
Aug 13, 2024

Cantargia presents the interim report for Q2 2024 on August 28 at 3.00 p.m.
Aug 9, 2024

(R) Cantargia reports progress and strong biomarker data from phase I clinical trial with CAN10
Jul 22, 2024

(R) Cantargia reports organisational change
<< Newer press releases    Older press releases >>

In media

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2026 · Cantargia AB